STRATEGY

The main elements of the company’s strategy for 2025 are to:

Drive clinical development forward and generate new efficacy data for arfolitixorin by conducting the phase Ib/II study in an efficient and time-optimized manner in collaboration with leading clinical experts; and lay a solid foundation for continued development and regulatory approval processes.

Maximize the potential of Isofol’s collaborations by nurturing established commercial and scientific collaborations; and identify and establish collaborations with additional clinical experts and partner companies to strengthen the further clinical development and commercialization of arfolitixorin.

Build trust in Isofol as a company and enable continued financing through transparent and open communication with shareholders, potential investors and partners, maintaining a high standard of regulatory compliance, and good cost control where value-creating activities are prioritized.

Last updated 04-15-2025